Snail expression and outcome in T1 high-grade and T2 bladder cancer: A retrospective Immunohistochemical analysis

BMC Urology

Volumn 13, Issue , 2013, Pages

  Nomura, Shunichiro ^a   Suzuki, Yasutomo ^a   Takahashi, Ryo ^a   Terasaki, Mika ^a   Kimata, Ryoji ^a   Hamasaki, Tsutomu ^a   Kimura, Go ^a   Shimizu, Akira ^a   Kondo, Yukihiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Bladder cancer; Chemotherapy; Prognostic marker; Snail

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; PREVALENCE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84890318167     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-13-73     Document Type: Article

References (23)

1. The present and future burden of urinary bladder cancer in the world. Ploeg M, Aben KK, Kiemeney LA, World J Urol 2009 27 3 289 293 10.1007/s00345-009-0383-3 19219610
2. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, Pagano F, J Urol 1999 161 5 1494 1497 10.1016/S0022-5347(05)68936-7 10210380 (Pubitemid 29420803)
3. Cystectomy for bladder cancer: a contemporary series. Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, Reuter V, J Urol 2001 165 4 1111 1116 10.1016/S0022-5347(05)66440-3 11257649 (Pubitemid 32210214)
4. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A, J Urol 1997 158 2 393 399 10.1016/S0022-5347(01)64487-2 9224310 (Pubitemid 27327674)
5. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG, J Clin Urol 2001 19 3 666 675 (Pubitemid 32120143)
6. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. Stein JP, Skinner DG, World J Urol 2006 24 3 296 304 10.1007/s00345-006-0061-7 16518661 (Pubitemid 44143761)
7. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, Eur Urol 2005 48 2 202 205 discussion 205-206 10.1016/j.eururo.2005.04.006 15939524 (Pubitemid 40957088)
8. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED, New Engl J Med 2003 349 9 859 866 10.1056/NEJMoa022148 12944571 (Pubitemid 37025405)
9. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, Malmstrom PU, Eur Urol 2004 45 3 297 303 10.1016/j.eururo.2003.09.019 15036674 (Pubitemid 38221402)
10. The role of serum cytokeratin 19 fragment in transarterial infusion against invasive bladder cancer. Takahashi R, Kimata R, Nomura S, Matsuzawa I, Suzuki Y, Hamasaki T, Kondo Y, Open J Urol 2013 3 3 160 164 10.4236/oju.2013. 33030
11. Epithelial-mesenchymal transitions in tumour progression. Thiery JP, Nature Rev Cancer 2002 2 6 442 454 10.1038/nrc822
12. Epithelial cell plasticity in development and tumor progression. Thiery JP, Chopin D, Cancer Metastasis Rev 1999 18 1 31 42 10.1023/A:1006256219004 10505544 (Pubitemid 29411090)
13. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES, Cell 2009 138 4 645 659 10.1016/j.cell.2009.06.034 19682730
14. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM, Clin Cancer Res 2006 12 14 Pt 1 4147 4153 16857785
15. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, Sancho E, Dedhar S, De Herreros AG, Baulida J, J Biol Chem 2002 277 42 39209 39216 10.1074/jbc.M206400200 12161443 (Pubitemid 35190890)
16. The Drosophila developmental gene snail encodes a protein with nucleic acid binding fingers. Boulay JL, Dennefeld C, Alberga A, Nature 1987 330 6146 395 398 10.1038/330395a0 3683556 (Pubitemid 18045471)
17. Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Bruyere F, Namdarian B, Corcoran NM, Pedersen J, Ockrim J, Voelzke BB, Mete U, Costello AJ, Hovens CM, Urologic Oncol 2010 28 6 591 596 10.1016/j.urolonc.2008.11.005
18. Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Kosaka T, Kikuchi E, Mikami S, Miyajima A, Shirotake S, Ishida M, Okada Y, Oya M, Clin Cancer Res 2010 16 23 5814 5823 10.1158/1078-0432.CCR-10-0230 20947514
19. Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer. Hoshino H, Miyoshi N, Nagai K, Tomimaru Y, Nagano H, Sekimoto M, Doki Y, Mori M, Ishii H, Biochem Biophys Res Commun 2009 390 3 1061 1065 10.1016/j.bbrc.2009.10.117 19861116
20. Expression of snail in pancreatic cancer promotes metastasis and chemoresistance. Yin T, Wang C, Liu T, Zhao G, Zha Y, Yang M, J Surg Res 2007 141 2 196 203 10.1016/j.jss.2006.09.027 17583745 (Pubitemid 47049639)
21. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J, Ann Oncol 2007 18 3 522 528 17229776 (Pubitemid 46359633)
22. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Font A, Taron M, Gago JL, Costa C, Sanchez JJ, Carrato C, Mora M, Celiz P, Perez L, Rodriguez D, Gimenez-Capitan A, Quiroga V, Benlloch S, Ibarz L, Rosell R, Ann Oncol 2011 22 1 139 144 10.1093/annonc/mdq333 20603439
23. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stohr R, Stockle M, Lehmann J, Schuler M, Hartmann A, Neoplasia 2010 12 8 628 636 20689757